12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies
Key Takeaways
- Classical Hodgkin Lymphoma (cHL) is characterized by pathognomonic CD15+ / CD30+ Reed-Sternberg cells and staged using the Lugano classification with PET-CT response assessed via the 5-point Deauville criteria (Scores 1–3 indicate complete metabolic response; Scores 4–5 indicate residual active disease).
- Frontline advanced cHL (Stage III/IV) treatment paradigms have shifted from ABVD to targeted and checkpoint-inhibitor chemoimmunotherapy: Nivolumab + AVD (N-AVD; SWOG S1826) demonstrates superior 2-year PFS (92% vs. 83%, HR 0.45) with reduced neuropathy and febrile neutropenia compared to Brentuximab Vedotin + AVD (A+AVD; ECHELON-1), while A+AVD remains an established standard requiring mandatory primary G-CSF prophylaxis.
- Bleomycin pulmonary toxicity (BPT) risk increases with cumulative doses >=400 units, age >60, impaired renal clearance, G-CSF co-administration, and high FiO2 exposure; PET-adapted interim imaging (RATHL trial) permits safe bleomycin omission after 2 cycles for patients achieving Deauville 1–3 without compromising overall survival.
- Relapsed or refractory cHL management prioritizes non-cross-resistant second-line chemoimmunotherapy (e.g., BV + Nivolumab, BV + Bendamustine, or ICE/DHAP) to achieve a complete metabolic response (PET-negative status) prior to consolidation with high-dose chemotherapy and Autologous Hematopoietic Cell Transplantation (auto-HCT).
- Post-auto-HCT maintenance with brentuximab vedotin for up to 16 cycles significantly improves 5-year PFS (AETHERA trial, HR 0.52) in high-risk patients with primary refractory disease, early relapse within 12 months, or extranodal involvement at relapse.
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies
Hodgkin Lymphoma (HL) accounts for approximately 10% of all diagnosed lymphomas in the United States. It exhibits a distinctive bimodal age distribution, peaking in young adults aged 15–35 years and in older adults aged >=55 years. Modern risk-stratified, response-adapted chemoimmunotherapy regimens have established Hodgkin lymphoma as one of the most curable human malignancies, with 5-year overall survival rates exceeding 90% in early-stage disease and 80–85% in advanced-stage disease.
Board-certified oncology pharmacists (BCOP) play a central role in optimizing cure rates while mitigating long-term organ toxicities—specifically anthracycline cardiotoxicity, bleomycin-induced pulmonary fibrosis, secondary myeloid neoplasms, and fertility impairment—through rigorous biomarker interpretation, PET-adapted therapy adjustments, antimicrobial prophylaxis, and toxicity interception protocols.
1. Pathophysiology, Histopathology & Diagnostic Biomarkers
Hodgkin lymphoma is pathologically segregated into two major World Health Organization (WHO) categories based on morphology and immunophenotype:
- Classical Hodgkin Lymphoma (cHL; ~95% of cases)
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL; ~5% of cases)
+---------------------------------------------------------------------------------------------------+
| HODGKIN LYMPHOMA IMMUNOPHENOTYPIC MATRIX |
| |
| [CLASSICAL HODGKIN LYMPHOMA (cHL)] |
| - Pathognomonic Cell: Hodgkin and Reed-Sternberg (HRS) cells (multinucleated "owl-eyed") |
| - Characteristic Markers: **CD30+ (100%)**, **CD15+ (75-85%)**, PAX5+ (dim/weak) |
| - Negative Markers: CD45- (LCA), CD20- (or variable/weak in <20%), CD3- |
| - Microenvironment: Extensive inflammatory infiltrate (eosinophils, histiocytes, plasma cells) |
| - Four Subtypes: |
| 1. Nodular Sclerosis (NS; 70%): Lacunar cells, collagen bands, young females, mediastinal mass|
| 2. Mixed Cellularity (MC; 20-25%): Abundant RS cells, strong EBV association, older males |
| 3. Lymphocyte-Rich (LR; 5%): Best prognosis, background mature B-lymphocytes |
| 4. Lymphocyte-Depleted (LD; <1%): Few lymphocytes, aggressive, elderly / HIV-positive |
| |
| [NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL)] |
| - Pathognomonic Cell: Lymphocyte-predominant (LP) cells ("popcorn" cells) |
| - Characteristic Markers: **CD20+**, **CD45+ (LCA)**, **BCL6+**, CD79a+ |
| - Negative Markers: **CD30-**, **CD15-** |
| - Clinical Behavior: Indolent, late relapses, managed similar to indolent B-cell NHL |
+---------------------------------------------------------------------------------------------------+
2. Staging, Risk Stratification & PET Response Assessment
Lugano Modification of Ann Arbor Staging System
- Stage I: Involvement of a single lymph node region (I) or localized involvement of a single extralymphatic organ/site (IE).
- Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single extralymphatic organ with regional lymph node involvement on the same side of the diaphragm (IIE).
- Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which may include the spleen (IIIS).
- Stage IV: Multifocal or diffuse involvement of one or more extralymphatic organs (e.g., bone marrow, liver, lung) with or without associated lymph node involvement.
- Modifiers:
- A / B Symptoms: "B" designation denotes unexplained fever (>38°C), drenching night sweats, or unexplained loss of >10% baseline body weight within the preceding 6 months. "A" denotes the absence of these constitutional symptoms.
- Bulky Disease: Defined per Lugano as a single nodal mass >=10 cm in maximum dimension or a mediastinal mass exceeding one-third of the maximum internal transthoracic diameter on chest CT.
Early-Stage Risk Stratification (GHSG / EORTC Criteria)
Early-stage (Stage I–II) cHL is categorized into Early Favorable vs. Early Unfavorable based on clinical risk factors:
- Large mediastinal adenopathy (bulky mass >=10 cm or >0.33 thorax ratio)
- Age >=50 years
- Elevated erythrocyte sedimentation rate (ESR >=50 mm/h without B symptoms, or ESR >=30 mm/h with B symptoms)
-
=3–4 involved nodal areas
- Presence of extranodal extension (E-lesions)
Advanced-Stage International Prognostic Score (IPS / Hasenclever Score)
For advanced-stage (Stage III–IV) cHL, the IPS assigns 1 point for each of the following 7 baseline adverse factors (each point decreases 5-year freedom from progression by ~7–8%):
- Serum Albumin <4.0 g/dL
- Hemoglobin <10.5 g/dL
- Male gender
- Age >=45 years
- Stage IV disease
- Leukocytosis (WBC >=15,000/mcL)
- Lymphopenia (ALC <600/mcL or <8% of total WBC)
+---------------------------------------------------------------------------------------------------+
| DEAUVILLE 5-POINT PET RESPONSE CRITERIA (Lugano) |
| |
| [Score 1]: No FDG uptake above background |
| [Score 2]: FDG uptake <= mediastinal blood pool |
| [Score 3]: FDG uptake > mediastinal blood pool but <= liver background |
| ==> SCORES 1 to 3: Complete Metabolic Response (CMR / PET-Negative) |
| |
| [Score 4]: FDG uptake moderately higher than liver background at any site |
| [Score 5]: FDG uptake markedly higher than liver background and/or new FDG-avid lesions |
| [Score X]: New areas of uptake unlikely to be related to lymphoma (inflammatory/infection) |
| ==> SCORES 4 to 5: Residual Active Disease / Treatment Failure (PET-Positive) |
+---------------------------------------------------------------------------------------------------+
3. Frontline Systemic Treatment Regimens
+---------------------------------------------------------------------------------------------------+
| FRONTLINE ADVANCED CLASSICAL HODGKIN LYMPHOMA PARADIGM |
| |
| CLINICAL STAGE III or IV (or Stage I-II Unfavorable Bulky) |
| | |
| +-------------------------+-------------------------+ |
| | | |
| v v |
| [N-AVD REGIMEN] (Preferred) [A+AVD REGIMEN] (Established) |
| (SWOG S1826: Herrera et al. NEJM 2024) (ECHELON-1: Connors NEJM 2018 / Ansell 2022) |
| - Nivolumab: 240 mg IV D1, D15 - Brentuximab Vedotin: 1.2 mg/kg IV D1, D15 |
| - Doxorubicin: 25 mg/m2 IV D1, D15 - Doxorubicin: 25 mg/m2 IV D1, D15 |
| - Vinblastine: 6 mg/m2 IV D1, D15 - Vinblastine: 6 mg/m2 IV D1, D15 |
| - Dacarbazine: 375 mg/m2 IV D1, D15 - Dacarbazine: 375 mg/m2 IV D1, D15 |
| - Q28D x 6 Cycles (12 Doses) - Q28D x 6 Cycles (12 Doses) |
| - 2-Year PFS: 92% vs 83% (HR 0.45, p<0.001) - 6-Year OS: 93.9% vs 89.4% (HR 0.59) |
| - Neuropathy: Low (G3: 1%) - Peripheral Neuropathy: 67% (G3: 11%) |
| - G-CSF: As clinically indicated - PRIMARY G-CSF PROPHYLAXIS: MANDATORY! |
| - Toxicity: irAEs (Hypothyroidism 13%) - Bleomycin Omitted: ZERO Pulmonary Toxicity |
+---------------------------------------------------------------------------------------------------+
Detailed Analysis of Frontline Regimens
| Regimen | Drug Components & Dosing Schedule | Cycle Length & Duration | Key Clinical Trial Evidence | Primary Toxicities & Pharmacist Interventions |
|---|---|---|---|---|
| N-AVD | Nivolumab 240 mg IV (or 3 mg/kg in pediatrics)<br>Doxorubicin 25 mg/m2 IV<br>Vinblastine 6 mg/m2 IV (max 10 mg)<br>Dacarbazine 375 mg/m2 IV<br>All administered on Days 1 and 15 | 28 days x 6 cycles (12 total treatments) | SWOG S1826 (n=970; Herrera et al. NEJM 2024). Randomized vs. BV-AVD in patients >=12 years old. 2-year PFS: 92% vs. 83% (HR 0.45, p < 0.001). | Preferred Category 1 frontline regimen. Dramatically lower neuropathy and infection rates than BV-AVD. Monitor for immune-related adverse events (irAEs: hypothyroidism 13%, rash, transaminitis, colitis). G-CSF is used as-needed, not mandatory. |
| A+AVD | Brentuximab vedotin 1.2 mg/kg IV (max 120 mg)<br>Doxorubicin 25 mg/m2 IV<br>Vinblastine 6 mg/m2 IV (max 10 mg)<br>Dacarbazine 375 mg/m2 IV<br>All administered on Days 1 and 15 | 28 days x 6 cycles (12 total treatments) | ECHELON-1 (n=1,334; Connors et al. NEJM 2018; 6-year OS: Ansell et al. NEJM 2022). 6-year OS: 93.9% vs. 89.4% (HR 0.59, p = 0.009). | Primary G-CSF prophylaxis is mandatory starting at Cycle 1 Day 1 (without G-CSF, febrile neutropenia rate was 21%). High peripheral sensory neuropathy (67%; Grade 3 in 11%); dose-modify BV to 0.9 mg/kg for Grade 2, hold for Grade >=3. Zero bleomycin lung toxicity. |
| ABVD | Doxorubicin 25 mg/m2 IV<br>Bleomycin 10 units/m2 IV (max 10 units)<br>Vinblastine 6 mg/m2 IV (max 10 mg)<br>Dacarbazine 375 mg/m2 IV<br>All administered on Days 1 and 15 | 28 days x 2–6 cycles depending on stage | Historical standard. RATHL trial (Johnson et al. NEJM 2016): Bleomycin safely omitted after cycle 2 in PET2-negative (DS 1–3) patients without compromising 3-yr PFS (84.4% vs 85.7%). | Bleomycin pulmonary toxicity (BPT): cough, dyspnea, basilar crackles, drop in DLCO. Avoid G-CSF co-administration with bleomycin (exacerbates alveolar lung injury). Extravasation: Doxorubicin (vesicant -> dexrazoxane/cold); Vinblastine (vesicant -> hyaluronidase/warm). |
| Escalated BEACOPP | Bleomycin 10 mg/m2 D8<br>Etoposide 200 mg/m2 D1–3<br>Doxorubicin 35 mg/m2 D1<br>Cyclophosphamide 1250 mg/m2 D1<br>Vincristine 1.4 mg/m2 D8 (max 2 mg)<br>Procarbazine 100 mg/m2 PO D1–7<br>Prednisone 40 mg/m2 PO D1–14 | 21 days x 4–6 cycles + routine G-CSF support | GHSG HD18 Trial (Borstmann et al. Lancet 2017). High cure rates in high-risk advanced cHL; PET4-negative allows de-escalation to 4 total cycles. | High acute and late toxicities: severe neutropenic sepsis, secondary myelodysplasia / AML (1.5–3.0%), permanent infertility (>90% azoospermia in males, premature ovarian failure in females). Rarely used in the US given modern N-AVD / A+AVD options. |
4. Bleomycin Pulmonary Toxicity (BPT) & Pharmacist Interception Protocols
Bleomycin is an antineoplastic glycopeptide antibiotic that binds Fe(II) and oxygen to generate reactive oxygen species (ROS), causing DNA single- and double-strand breaks. Because lung tissue and skin are deficient in bleomycin hydrolase (the cytoplasmic deactivating aminopeptidase enzyme), the lung is uniquely vulnerable to oxidative endothelial injury, organizing alveolitis, and irreversible pulmonary fibrosis.
Clinical Risk Factors for BPT
- Cumulative lifetime dose >=400 units (incidence rises sharply above 400 units; absolute ceiling typically 400 units)
- Age >60 years
- Renal insufficiency (creatinine clearance <50–60 mL/min; 60–70% of bleomycin is renally excreted intact)
- High fraction of inspired oxygen (FiO2 >30–40% during general anesthesia or supplemental O2 triggers fatal ARDS)
- Prior mediastinal radiation therapy
- Concomitant administration of granulocyte colony-stimulating factors (G-CSF / filgrastim / pegfilgrastim), which amplifies alveolar neutrophil influx and superoxide generation
+---------------------------------------------------------------------------------------------------+
| BLEOMYCIN PULMONARY TOXICITY (BPT) MONITORING & MANAGEMENT |
| |
| BASELINE ASSESSMENT: |
| - Pulmonary Function Tests (PFTs) with DLCO (Diffusing Capacity of the Lung for Carbon Monoxide)|
| - Baseline 2D-Echocardiogram (LVEF for doxorubicin) and baseline renal function (CrCl) |
| |
| INTERIM PET-ADAPTED PROTOCOL (RATHL Protocol): |
| - Perform PET-CT after Cycle 2 (PET2) |
| - If Deauville Score 1 - 3 (PET-negative): **OMIT BLEOMYCIN from Cycles 3 to 6 (AVD alone)** |
| - If Deauville Score 4 - 5 (PET-positive): Escalate therapy to escalated BEACOPP or Salvage |
| |
| CLINICAL SYMPTOM SURVEILLANCE & ACTIONS: |
| - Symptoms: Nonproductive dry cough, exertional dyspnea, pleuritic substernal pain, fever |
| - Physical Exam: Bilateral inspiratory dry "velcro" basilar crackles (crepitations) |
| - PFT Trigger: Drop in **DLCO >=15-20% from baseline** OR new interstitial infiltrates on CT |
| - IMMEDIATE ACTION: **PERMANENTLY DISCONTINUE BLEOMYCIN!** (Never rechallenge!) |
| - Pharmacotherapy: High-dose systemic corticosteroids (Prednisone 0.75-1 mg/kg/day or IV |
| Methylprednisolone 1-2 mg/kg/day) tapered over 4 to 8 weeks |
+---------------------------------------------------------------------------------------------------+
5. Relapsed & Refractory Classical Hodgkin Lymphoma Management
Approximately 10–15% of patients with early-stage cHL and 20–30% with advanced-stage cHL experience primary refractory disease (failure to achieve CMR or progression within 3 months of frontline therapy) or disease relapse.
Therapeutic Algorithm for Transplant-Eligible Relapse
The standard curative-intent strategy for chemosensitive relapsed/refractory cHL in transplant-eligible patients is Second-Line Salvage Therapy to achieve Complete Metabolic Response (PET-negative) followed by High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation (auto-HCT).
+---------------------------------------------------------------------------------------------------+
| RELAPSED / REFRACTORY cHL SALVAGE & CONSOLIDATION ALGORITHM |
| |
| BIOPSY-PROVEN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
| | |
| v |
| [SECOND-LINE SYSTEMIC SALVAGE CHEMOIMMUNOTHERAPY] |
| - Option 1 (Preferred Novel): **Brentuximab Vedotin + Nivolumab** (Moskowitz 2021; CMR ~67-79%) |
| - Option 2 (Immune Backbone): **Pembrolizumab + GVD** (Gemcitabine, Vinorelbine, Liposomal Dox)|
| - Option 3 (Cytotoxic Salvage): **ICE** (Ifosfamide, Carboplatin, Etoposide + Mesna) OR |
| **DHAP** (Dexamethasone, High-Dose Cytarabine, Cisplatin) OR |
| **IGEV** (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone) |
| | |
| v |
| [INTERIM RESTAGING PET-CT SCAN] |
| | |
| +-------------------------+-------------------------+ |
| | | |
| v v |
| [PET-NEGATIVE: Deauville 1-3] [PET-POSITIVE: Deauville 4-5] |
| | | |
| v v |
| [HIGH-DOSE CHEMOTHERAPY (BEAM) + AUTO-HCT] [NON-CROSS-RESISTANT THIRD-LINE SALVAGE] |
| - Carmustine (BCNU) 300 mg/m2 D-6 - Switch to PD-1 inhibitor (Pembrolizumab) |
| - Etoposide 100-200 mg/m2 BID D-5 to D-2 or Brentuximab Vedotin if not yet exposed |
| - Cytarabine 100-200 mg/m2 BID D-5 to D-2 - Goal: Attain CMR prior to Auto-HCT |
| - Melphalan 140 mg/m2 D-1 | |
| - Stem Cell Infusion Day 0 v |
| | [Consolidate with Auto-HCT once PET-negative]|
| v |
| [POST-TRANSPLANT MAINTENANCE EVALUATION] |
| - Assess AETHERA Risk Criteria: |
| * Primary refractory disease (no complete remission to frontline therapy) |
| * Early relapse (<12 months from completion of frontline therapy) |
| * Extranodal disease involvement at the time of relapse pre-salvage |
| - If High-Risk (>=1 factor present): **BRENTUXIMAB VEDOTIN MAINTENANCE** |
| * Dose: 1.8 mg/kg IV every 3 weeks starting Day +30 to +45 post-HCT |
| * Duration: Up to 16 cycles (~1 year) |
| * AETHERA Trial: 5-year PFS 59% vs. 41% (HR 0.52, p < 0.001) |
+---------------------------------------------------------------------------------------------------+
Post-Transplant & Third-Line Systemic Targeted Agents
| Therapeutic Agent | Mechanism & Regimen | Landmark Clinical Trial Data | Toxicity Profile & Clinical Monitoring |
|---|---|---|---|
| Pembrolizumab | Anti-PD-1 monoclonal antibody<br>Dose: 200 mg IV Q3W or 400 mg IV Q6W | KEYNOTE-204 (n=304; Kuruvilla et al. Lancet Oncol 2021). Randomized vs. Brentuximab vedotin in post-auto-HCT or transplant-ineligible relapse. Median PFS: 13.2 vs. 8.3 months (HR 0.65, p = 0.0027). | Immune-related adverse events: pneumonitis (11%), colitis, endocrinopathies (hypothyroidism/hyperthyroidism 19%), hepatitis. High response in 9p24.1 amplified cHL. |
| Nivolumab | Anti-PD-1 monoclonal antibody<br>Dose: 240 mg IV Q2W or 480 mg IV Q4W | CheckMate 205 (Ansell et al. Lancet Oncol 2016). Evaluated in cohorts post-auto-HCT and post-BV. Overall response rate: 69–73%, median duration of response >16 months. | Similar irAE profile to pembrolizumab. Note: Checkpoint inhibitors administered prior to allogeneic HCT increase risks of hyperacute/severe GVHD and graft failure. |
| Brentuximab Vedotin | Anti-CD30 antibody-drug conjugate linked via protease-cleavable linker to monomethyl auristatin E (MMAE)<br>Dose: 1.8 mg/kg IV Q3W | Pivotal Phase 2 (Younes et al. JCO 2012) and AETHERA Maintenance Trial (Moskowitz et al. Lancet 2015). Post-HCT maintenance 5-year PFS 59% vs 41% (HR 0.52). | Peripheral sensory neuropathy (56–67%), neutropenia, anemia, rare progressive multifocal leukoencephalopathy (PML). Strong CYP3A4 inhibitors increase MMAE AUC. |
A 26-year-old male is diagnosed with Stage IVB Classical Hodgkin Lymphoma (nodular sclerosis subtype, IPS = 4). He initiates frontline chemoimmunotherapy with Nivolumab, Doxorubicin, Vinblastine, and Dacarbazine (N-AVD) per the SWOG S1826 protocol. In comparing N-AVD to Brentuximab Vedotin plus AVD (A+AVD from ECHELON-1), which of the following statements accurately reflects the clinical trial evidence and supportive care requirements for this patient?
A 62-year-old female with Stage IIA non-bulky classical Hodgkin lymphoma completes 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). Her interim restaging PET-CT scan demonstrates complete metabolic response with a Deauville score of 2 (PET2-negative). Her baseline serum creatinine was 0.8 mg/dL (CrCl 78 mL/min), but recent labs show a serum creatinine of 1.4 mg/dL (CrCl 38 mL/min). She reports no respiratory complaints. Based on the landmark RATHL trial and bleomycin pharmacology, what is the most appropriate pharmacist recommendation for Cycles 3 through 6?
A 29-year-old male experiences a biopsy-proven relapsed classical Hodgkin lymphoma 8 months after completing 6 cycles of frontline ABVD. He is fit, has normal organ function, and is a candidate for autologous stem cell transplantation. He receives 3 cycles of second-line Brentuximab Vedotin plus Nivolumab salvage chemoimmunotherapy, and restaging PET-CT confirms a complete metabolic response (Deauville score 1). He successfully proceeds to BEAM high-dose conditioning and autologous hematopoietic stem cell transplantation. Which post-transplant management plan is supported by Category 1 evidence from the AETHERA trial?
A 31-year-old female receiving frontline ABVD for Stage IIB classical Hodgkin lymphoma develops a new-onset nonproductive cough, mild exertional dyspnea, and bilateral fine end-inspiratory crackles on pulmonary auscultation prior to Cycle 4 Day 1. Repeat pulmonary function testing demonstrates an 18% decline in DLCO compared to baseline, and high-resolution chest CT shows bilateral subpleural reticular opacities and ground-glass infiltrates without pulmonary embolism or infection. What is the most appropriate immediate clinical intervention?